160 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
late-breaking presentations. The presented data across AbbVie and Allergan Aesthetics' extensive portfolios reinforce the companies' ongoing commitment
424B5
ABBV
Abbvie Inc
26 Feb 24
Prospectus supplement for primary offering
6:12am
in effect from time to time. Based on AbbVie’s credit rating on the date hereof, the applicable margin is 0.875%.
Bridge Loan Commitment Letter …
In connection with our entry into the Acquisition Agreements, we obtained a commitment letter from Morgan Stanley Senior Funding, Inc. and certain other
424B5
kddqar1gorlrpzk87br2
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
8wgi1bai44ryyrdp p5t
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.1
zvv2fxyr85e lul
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
wbxjggqfhfp24ai gh
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
PX14A6G
qym3i 4gm0s6u83
4 May 23
Letter to shareholders
8:08am
PX14A6G
rwu c30yfgorrok
11 Apr 23
Letter to shareholders
12:34pm
8-K
EX-99.1
fbkkrcboj991y6
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am
8-K
EX-3.1
zesn1do 44n5u6q82
14 Oct 22
Departure of Directors or Certain Officers
5:02pm